Evidence map›Paper›PMID 33037656›Full record

Trial reportClinical endocrinology2021

Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease.

Chelsea S Pan, Julian J Weiss, Lindsay T Fourman, Colleen Buckless, Karen L Branch, Hang Lee, Martin Torriani, Madhusmita Misra, Takara L Stanley

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Increased GH/IGF-I Axis Activity Relates to Lower Hepatic Lipids and Phosphor Metabolism.The Journal of clinical endocrinology and metabolism · 2023
    Article
  15. Growth hormone and nonalcoholic fatty liver disease.Immunometabolism (Cobham, Surrey) · 2023 · on this map
    Review
  16. Review
  17. Nonalcoholic fatty liver disease and non-liver comorbidities.Clinical and molecular hepatology · 2023
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chelsea S PanMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Julian J WeissMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Lindsay T FourmanMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Colleen BucklessDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Karen L BranchTranslational and Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA.
Hang LeeBiostatistics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Martin TorrianiDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Madhusmita MisraPediatric Endocrine Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Takara L StanleyMetabolism Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-2336-2958
Harvard University · USMassachusetts General Hospital · US

Funding

ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2025
$6.0M
NICHD NIH HHS K23 HD100266NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

backgroundNonalcoholic fatty liver disease (NAFLD) is highly prevalent in young adults with obesity. Obesity is associated with relative growth hormone (GH) deficiency, and data from animal studies and from humans with pituitary GH deficiency suggest a role for GH deficiency in the pathogenesis of NAFLD. The effects of GH on NAFLD in those with obesity are unknown, however, prompting this pilot study to assess effects of GH administration on measures of NAFLD in young adults.

methodsTwenty-four men and women aged 18-29 years with BMI ≥ 30 kg/m

resultsCompared to no treatment, the effect size of rhGH on absolute HFF over 24 weeks was -3.3% (95% confidence interval: -7.8%, 1.2%; p = .14). At 24 weeks, HFF < 5% was achieved in 5 of 9 individuals receiving rhGH versus 1 of 9 individuals receiving no treatment (p = .04). rhGH did not significantly reduce ALT, AST or GGT. Serum IGF-1 increased as expected with rhGH treatment, and there were no changes in fasting lipids, C-reactive protein, fasting glucose or 2-h glucose following an oral glucose tolerance test.

conclusionData from this pilot study suggest that rhGH treatment in young adults with obesity and NAFLD may have benefits to reduce liver fat content, although larger studies are needed to confirm this effect.

Indexed as

Dwarfism, PituitaryHuman Growth HormoneNon-alcoholic Fatty Liver DiseaseFemaleGrowth HormoneHumansInsulin-Like Growth Factor IMalePilot ProjectsYoung AdultGrowth HormoneHuman Growth HormoneInsulin-Like Growth Factor Iconditions: obesity/lipids/nutritiongrowth hormonehormones/related: pituitarynonalcoholic fatty liver diseaseobesity

Identifiers

PMID33037656
PMCPMC9284460
OpenAlexW3092066421

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.